Combining expertise in discovery and development of peptide therapeutics with unique peptide libraries to identify novel peptide drug candidates In ...
Combining expertise in discovery and development of peptide therapeutics with unique peptide libraries to identify novel peptide drug candidates In ...
... which are designed to direct immune T cells to cancer cells, while incorporating a masking peptide to reduce binding to healthy tissues and prevent ...
Lonza cited increasing demand for clinical-stage manufacturing and said “the acquisition of the site will provide additional cGMP capacity and will ...
... therapies to target solid tumors, announces that the US Patent and Trademark Office has granted US Patent no 9,775,892, Peptide mixture.
ITCA 650 is an implantable pump designed to deliver a continuous supply of the glucagon-like peptide-1 agonist exenatide, which is the active ...
Lutathera, a peptide receptor radionuclide therapy, is the company's first drug approved as a therapeutic drug for GEP-NET. However, Advanced ...
SHIRLEY - SEP 30TH, 2017 - The team led by researchers from New York University and Washington University recently published a new study on Science Signaling, which is related to the PDX models being applied to describe the proteome of breast tumors. Read more...
Peptilogics, a Pittsburgh, PA- and San Jose, CA-based pre-clinical stage company utilizing an innovative peptide platform to treat multidrug-resistant bacterial infections, closed a $5.5m Series A financing.
Backers included Peter Thiel, Stefan Roever, BlueTree Ventures and others. Read more...
BAGSVAERD, Denmark I September 29, 2017 I Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Fiasp® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment of adults with diabetes. The FDA's decision comes after Fiasp® in clinical trials demonstrated benefits for people in need of improved overall glucose control. Read more...
Peter Thiel has invested in Peptilogics. The Paypal founder contributed to the $5.5 million series A Peptilogics put together to advance its lead treatment for multidrug-resistant bacterial infections toward an IND.
Thiel joined with Stefan Roever, BlueTree Ventures and others to power Peptilogics to the series A. The financing follows the generation of preclinical data Peptilogics says suggest its platform and, in particular, its lead candidate can take out a broad spectrum of resistant bacteria. Those data have put Peptilogics in a position to work toward filing an IND next year. Read more...